Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 52

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 52
---
 a part of, and is not incorporated into, this Proxy Statement, and you should not consider it part of this this Proxy Statement.

| Cytokinetics, Inc.|2025 Proxy Statement |     | 35 |

TABLE OF CONTENTS Board of Directors Communicating with the Board of Directors We do not have a formal policy regarding stockholder communication with the Board of Directors. Our stockholders may communicate directly with the Board of Directors in writing, addressed to: Board of Directors c/o John O. Faurescu, Esq., Corporate Secretary Cytokinetics, Incorporated 350 Oyster Point Blvd. South San Francisco, California 94080 or by email to: investor@cytokinetics.com The Secretary will review each stockholder communication. The Secretary will forward to the Chairman of the Board of Directors or to the entire Board of Directors as he may determine is advisable (or to members of a Board of Directors’ committee, if the communication relates to a subject matter clearly within that committee’s area of responsibility) each communication that relates to our business or governance if the communication: (i) is not offensive, (ii) is legible in form and reasonably understandable in content, and (iii) is not merely related to a personal grievance against us or an individual or the purpose of which is to further a personal interest not shared by the other stockholders generally. Stockholders who would like their submissions directed to an individual member of the Board of Directors may so specify, and the communication will be forwarded, as appropriate.

| 36 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS

Executive Officer The following table sets forth the names of our executive officers and their ages and positions with us as of April 10, 2025.

| Name                       |     | Age |     | Position                                           |
| Robert I. Blum             |     |  61 |     | President and Chief Executive Officer              |
| Andrew M. Callos           |     |  56 |     | Executive Vice President, Chief Commercial Officer |
| Sung H. Lee                |     |  54 |     | Executive Vice President, Chief Financial Officer  |
| Fady I. Malik, M.D., Ph.D. |     |  60 |     | Executive Vice President, Research and Development |

Executive Officer Skills, Experience and Background Robert I. Blum’s biography is set forth under “Board of Directors” above. Andrew M. Callos has served as our Executive Vice